ClinicalTrials.gg

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Philogen and Lantheus side by side

Their registered studies and the programs behind them, as ClinicalTrials.gov shows them and the companies' own pipelines name them. Counts, not rankings: the companies differ in size, so each number is shown beside its share of that company's own programs.

At a glance

Studies each sponsor leads, with the companies grouped under it. Every number opens the studies it counts.

PhilogenLantheus
studies on the registry4977
open to participants now164
phase 3 studies under way32
reach primary completion within a year11
programswith a study of their own in two years64

Pipeline by phase

Each program once, at the furthest phase its own studies reached. The bar is the share of that company's programs, so a small company and a large one read on the same scale.

Furthest phasePhilogenLantheus
Phase 1

Philogen: 1 of its 6 programs at phase 1

  1. Gallium-68phase 1
17%
00%
Phase 2

Philogen: 2 of its 6 programs at phase 2

  1. F8IL10phase 2
  2. Lomustinephase 2
33%

Lantheus: 1 of its 4 programs at phase 2

  1. Lutetium Lu 177-DOTA-DUNP19 LNTH2403phase 2
25%
Phase 3

Philogen: 3 of its 6 programs at phase 3

  1. onfekafusp alfaphase 3
  2. daromunphase 3
  3. darleukinphase 3
50%

Lantheus: 1 of its 4 programs at phase 3

  1. Gallium-68phase 3
25%
Approved, new studies00%

Lantheus: 2 of its 4 programs at approved, new studies

  1. florbetaben f-18approved, new study
  2. piflufolastatapproved, new study
50%

Readouts ahead

Programs whose next study reaches primary completion in each month, by the sponsor's own estimate. A ring marks a month with a phase 3 readout.

Nov ’26DecJan ’27FebMarAprMayJunJulAugSepOct
Philogen0 readouts · 0 phase 3············
Lantheus1 readouts · 0 phase 3·········

Lantheus, Aug ’27: 1 program whose next study reaches primary completion

  1. Lutetium Lu 177-DOTA-DUNP19 LNTH2403phase 2 · Aug 0 · NCT07357519
··
size: programs that monthincludes phase 3Dates are estimates the sponsors file and often move.

Changed in the last 90 days

Since Aug 22, 2026: programs whose first study was registered, programs that reached a new phase, studies stopped, and primary completions moved later (a month or more in phase 3, three otherwise). Stops and dates are read from the registry’s changes, kept since Sep 25, 2026.

Philogen

New programs 0

None

Reached a new phase 0

None

Study stopped 0

None

Primary completion later 0

None

Lantheus

New programs 0

None

Reached a new phase 1

Study stopped 0

None

Primary completion later 0

None

Where they overlap

Conditions where at least two of them have programs: 5 in all. A program counts in each condition its studies name most.

ConditionPhilogenLantheus
Colorectal Neoplasmsboth · compare here

Philogen in Colorectal Neoplasms: 2 programs

  1. darleukinphase 3
  2. Gallium-68phase 1

Their studies: Philogen’s studies of Colorectal Neoplasms in search

Lantheus in Colorectal Neoplasms: 2 programs

  1. Gallium-68phase 3
  2. Lutetium Lu 177-DOTA-DUNP19 LNTH2403phase 2

Their studies: Lantheus’s studies of Colorectal Neoplasms in search

Carcinoma, Renal Cellboth · compare here

Philogen in Carcinoma, Renal Cell: 1 program

  1. Gallium-68phase 1

Their studies: Philogen’s studies of Carcinoma, Renal Cell in search

Lantheus in Carcinoma, Renal Cell: 2 programs

  1. Gallium-68phase 3
  2. piflufolastatapproved, new study

Their studies: Lantheus’s studies of Carcinoma, Renal Cell in search

Prostatic Neoplasmsboth · compare here

Philogen in Prostatic Neoplasms: 1 program

  1. Gallium-68phase 1

Their studies: Philogen’s studies of Prostatic Neoplasms in search

Lantheus in Prostatic Neoplasms: 2 programs

  1. Gallium-68phase 3
  2. piflufolastatapproved, new study

Their studies: Lantheus’s studies of Prostatic Neoplasms in search

Breast Neoplasmsboth · compare here

Philogen in Breast Neoplasms: 1 program

  1. Gallium-68phase 1

Their studies: Philogen’s studies of Breast Neoplasms in search

Lantheus in Breast Neoplasms: 1 program

  1. Gallium-68phase 3

Their studies: Lantheus’s studies of Breast Neoplasms in search

Urinary Bladder Neoplasmsboth · compare here

Philogen in Urinary Bladder Neoplasms: 1 program

  1. Gallium-68phase 1

Their studies: Philogen’s studies of Urinary Bladder Neoplasms in search

Lantheus in Urinary Bladder Neoplasms: 1 program

  1. Gallium-68phase 3

Their studies: Lantheus’s studies of Urinary Bladder Neoplasms in search

Same targetBetaPro · free during the beta

Programs that act on the same gene, from the company’s own words, a judged reading of NCIt, ChEMBL or the studies, or a rule. A reading by rule is marked rule.

A target, or a pathogen for a vaccine, known for: Philogen 3 of 6 · Lantheus 3 of 4 programs (4 of them by rule). Most early programs are named only by a code and their companies do not say what they act on, so this list is short and grows as targets are read.

What this can't show

  • Only what ClinicalTrials.gov holds: programs run only in other registries are missing.
  • Grouping is ours: subsidiaries and acquisitions counted under the parent, each dated and sourced on the sponsor page.
  • Readout dates are the sponsors’ estimates, not results.
  • A program is a drug as the registry names it: a code its company has not tied to a name counts on its own until it is read, and a study run under a partner’s name counts for the partner.
  • “Same target” covers only the programs whose target is known, from the company’s words, a judged reading or a rule; most early programs say nothing of it.